Arcturus Therapeutics presents research on mRNA therapy for inherited metabolic disorders at SIMD 2026

Arcturus Therapeutics presents research on mRNA therapy for inherited metabolic disorders at SIMD 2026
Arcturus Therapeutics unveils SIMD 2026 research

Arcturus Therapeutics presented a new research poster at the Society for Inherited Metabolic Disorders (SIMD) 2026 Annual Meeting.

The company highlighted its ongoing efforts in developing mRNA-based treatments for urea cycle disorders (UCD) and ornithine transcarbamylase (OTC) deficiency. Attendees who missed the live presentation are encouraged to review the poster online. This development underscores Arcturus Therapeutics' continued commitment to advancing innovative therapies for rare genetic metabolic conditions.

Arcturus Therapeutics previously announced it would present research on mRNA-based therapies for OTC deficiency at the SIMD 2026 Annual Meeting. The company has also reported that 10 percent of cystic fibrosis patients remain untreated by current therapies. These efforts highlight Arcturus's ongoing focus on rare genetic and metabolic conditions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.